AU2015373996B2 - Derivatives and methods of treating hepatitis B infections - Google Patents

Derivatives and methods of treating hepatitis B infections Download PDF

Info

Publication number
AU2015373996B2
AU2015373996B2 AU2015373996A AU2015373996A AU2015373996B2 AU 2015373996 B2 AU2015373996 B2 AU 2015373996B2 AU 2015373996 A AU2015373996 A AU 2015373996A AU 2015373996 A AU2015373996 A AU 2015373996A AU 2015373996 B2 AU2015373996 B2 AU 2015373996B2
Authority
AU
Australia
Prior art keywords
alkyl
compound
umol
mixture
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015373996A
Other languages
English (en)
Other versions
AU2015373996A1 (en
Inventor
George D. Hartman
Scott Kuduk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novira Therapeutics LLC
Original Assignee
Novira Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novira Therapeutics LLC filed Critical Novira Therapeutics LLC
Publication of AU2015373996A1 publication Critical patent/AU2015373996A1/en
Priority to AU2020233640A priority Critical patent/AU2020233640A1/en
Application granted granted Critical
Publication of AU2015373996B2 publication Critical patent/AU2015373996B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2015373996A 2014-12-30 2015-12-30 Derivatives and methods of treating hepatitis B infections Ceased AU2015373996B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020233640A AU2020233640A1 (en) 2014-12-30 2020-09-15 Derivatives and methods of treating hepatitis B infections

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462097835P 2014-12-30 2014-12-30
US62/097,835 2014-12-30
US201562163150P 2015-05-18 2015-05-18
US62/163,150 2015-05-18
PCT/US2015/068099 WO2016109689A2 (en) 2014-12-30 2015-12-30 Derivatives and methods of treating hepatitis b infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020233640A Division AU2020233640A1 (en) 2014-12-30 2020-09-15 Derivatives and methods of treating hepatitis B infections

Publications (2)

Publication Number Publication Date
AU2015373996A1 AU2015373996A1 (en) 2017-07-13
AU2015373996B2 true AU2015373996B2 (en) 2020-10-08

Family

ID=56163427

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015373996A Ceased AU2015373996B2 (en) 2014-12-30 2015-12-30 Derivatives and methods of treating hepatitis B infections
AU2020233640A Abandoned AU2020233640A1 (en) 2014-12-30 2020-09-15 Derivatives and methods of treating hepatitis B infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020233640A Abandoned AU2020233640A1 (en) 2014-12-30 2020-09-15 Derivatives and methods of treating hepatitis B infections

Country Status (10)

Country Link
US (11) US9527845B2 (enExample)
EP (1) EP3240787A4 (enExample)
JP (1) JP6713465B2 (enExample)
KR (1) KR20170118706A (enExample)
CN (1) CN107531691A (enExample)
AU (2) AU2015373996B2 (enExample)
CA (1) CA2972434A1 (enExample)
MX (1) MX383929B (enExample)
RU (1) RU2742305C2 (enExample)
WO (3) WO2016109689A2 (enExample)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2794565B1 (en) 2011-12-21 2017-07-26 Novira Therapeutics Inc. Hepatitis b antiviral agents
CA2881057C (en) 2012-08-28 2020-10-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
JP6466348B2 (ja) 2013-02-28 2019-02-06 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
HUE040446T2 (hu) 2013-05-17 2019-03-28 Janssen Sciences Ireland Uc Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére
TW202126620A (zh) 2013-05-17 2021-07-16 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP6553059B2 (ja) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Ｈｂｖ感染の治療のための併用療法
PL3102572T3 (pl) 2014-02-06 2019-04-30 Janssen Sciences Ireland Uc Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
WO2016109689A2 (en) 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017011552A1 (en) 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
AR106192A1 (es) 2015-09-29 2017-12-20 Novira Therapeutics Inc Formas cristalinas de un agente antiviral contra la hepatitis b
KR102398439B1 (ko) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
WO2017181141A2 (en) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
EP3468561A4 (en) 2016-06-10 2019-12-04 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
TW201806956A (zh) 2016-06-29 2018-03-01 諾維拉治療公司 二氮呯酮衍生物及治療ｂ型肝炎感染之方法
CA3029566A1 (en) 2016-06-29 2018-01-04 Novira Therapeutics, Inc. Diazepinone derivatives and their use in the treatment of hepatitis b infections
WO2018011100A1 (en) * 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag Novel tetrahydropyrazolopyridine compounds for the treatment of infectious diseases
WO2018011163A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
WO2018011160A1 (en) * 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
CN109415368B (zh) * 2016-07-14 2021-04-30 豪夫迈·罗氏有限公司 用于治疗感染性疾病的羧基6,7-二氢-4H-吡唑并[1,5-a]吡嗪化合物
EP4059934B1 (en) 2016-09-09 2026-07-29 Novartis AG Compounds and compositions as inhibitors of endosomal toll-like receptors
KR20230010826A (ko) 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
SG11202001685TA (en) 2017-08-28 2020-03-30 Enanta Pharm Inc Hepatitis b antiviral agents
EA202091113A1 (ru) * 2017-11-02 2020-08-28 Айкурис Гмбх Унд Ко. Кг Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv)
MX2020004838A (es) 2017-11-02 2020-10-16 Aicuris Gmbh & Co Kg Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
US11572372B2 (en) 2017-11-16 2023-02-07 Medshine Discovery Inc. Anti-HBVtetrahydroisoxazolo[4,3-c]pyridine compounds
WO2019097479A1 (en) * 2017-11-17 2019-05-23 Novartis Ag Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
US10723733B2 (en) 2017-12-06 2020-07-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド
JP2021506852A (ja) * 2017-12-21 2021-02-22 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｈｂｖ感染と関連する疾患を治療するためのイソキサゾール化合物
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
SG11202007097QA (en) 2018-03-14 2020-08-28 Janssen Sciences Ireland Unlimited Co Capsid assembly modulator dosing regimen
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
CN110437132B (zh) * 2018-05-04 2022-04-01 上海长森药业有限公司 双并杂环核衣壳抑制剂及其药物用途
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
TW202024093A (zh) 2018-09-21 2020-07-01 美商安塔製藥公司 作為抗病毒劑之官能化雜環
MA53721A (fr) 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
IL328538A (en) * 2018-10-05 2026-07-01 Univ Emory Monomeric and multimeric hepatitis B antivirals
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
AR117188A1 (es) * 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
US20220009945A1 (en) 2018-11-02 2022-01-13 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-thiazole[5,4-c]pyridines active against the hepatitis b virus (hbv)
PY1991611A (es) 2018-11-02 2022-03-14 Aicuris Gmbh & Co Kg Nueva urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
AR116947A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
UY38434A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
PY1991606A (es) * 2018-11-02 2022-02-10 Aicuris Gmbh & Co Kg Nueva urea 6,7-dihidro-4h-pirazolo [4,3-c] piridinas activas contra el virus de la hepatitis b (vhb)
EP3883570A4 (en) 2018-11-21 2022-07-13 Enanta Pharmaceuticals, Inc. FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
CN111333590B (zh) * 2018-12-18 2022-05-17 沈阳中化农药化工研发有限公司 一种异恶唑烷盐酸盐的制备方法
AU2020223865A1 (en) 2019-02-22 2021-07-15 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
CN113574063B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸及其前药
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
PH12021552191A1 (en) * 2019-03-14 2022-08-15 Janssen Sciences Ireland Unlimited Co Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US20220306647A1 (en) 2019-04-30 2022-09-29 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitus b virus (hbv)
EP3962909B1 (en) 2019-04-30 2023-10-04 AiCuris GmbH & Co. KG Novel oxalyl piperazines active against the hepatitis b virus (hbv)
KR20220002498A (ko) 2019-04-30 2022-01-06 아이쿠리스 게엠베하 운트 코. 카게 B형 간염 바이러스 (hbv)에 대해 활성인 신규 인돌리진-2-카르복스아미드
MX2021013086A (es) 2019-04-30 2021-11-17 Aicuris Gmbh & Co Kg Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb).
BR112021021454A2 (pt) 2019-05-06 2021-12-21 Janssen Sciences Ireland Unlimited Co Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
WO2020228745A1 (zh) * 2019-05-14 2020-11-19 正大天晴药业集团股份有限公司 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物的晶型
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
UY38705A (es) * 2019-05-23 2020-12-31 Irbm S P A Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b
KR20220012320A (ko) * 2019-05-28 2022-02-03 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv 캡시드 조립 조절제로서의 디플루오로 아제판
US20220242879A1 (en) * 2019-05-28 2022-08-04 Janssen Sciences Ireland Unlimited Company Fused heterocycle derivatives
KR20220015426A (ko) * 2019-05-28 2022-02-08 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 캡시드 조립 조절제로서의 융합 복소환 유도체
US20220323455A1 (en) * 2019-05-28 2022-10-13 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives as antiviral agents
MX2021014578A (es) * 2019-05-28 2022-03-17 Janssen Sciences Ireland Unlimited Co Azepinas como moduladores del ensamblaje de la cápside del vhb.
CR20210666A (es) * 2019-05-28 2022-03-11 Janssen Sciences Ireland Unlimited Co Derivados heterocíclicos condensados
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021023662A1 (en) * 2019-08-02 2021-02-11 Janssen Sciences Ireland Unlimited Company Pyrazolo[4,3-c]pyridine compounds for use in the treatment of hbv infection
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
US12410418B2 (en) 2019-12-06 2025-09-09 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
CN113264931B (zh) * 2020-02-17 2022-06-07 成都先导药物开发股份有限公司 一种1,4,6,7-四氢-5H-吡唑并[4,3-c]吡啶衍生物的制备方法
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
KR102987126B1 (ko) 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
CA3176946A1 (en) * 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
GB202103704D0 (en) * 2021-03-17 2021-04-28 Pathios Therapeutics Ltd Compounds
KR20230022433A (ko) * 2020-06-05 2023-02-15 파티오스 테라퓨틱스 리미티드 Gpr65의 조절제로서 n-(페닐아미노카보닐) 테트라하이드로-이소퀴놀린 및 관련 화합물
LT4192474T (lt) 2020-08-07 2025-11-25 Fosfonamidų nukleotidų analogų provaistai ir jų farmacinis panaudojimas
WO2022053010A1 (en) * 2020-09-11 2022-03-17 Janssen Sciences Ireland Unlimited Company Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202237617A (zh) * 2020-12-02 2022-10-01 愛爾蘭商健生科學愛爾蘭無限公司 稠合雜環衍生物
US20240269142A1 (en) 2021-05-13 2024-08-15 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
TW202325279A (zh) 2021-10-29 2023-07-01 美商阿克思生物科學有限公司 HIF-2α抑制劑及其使用方法
CN119176776A (zh) * 2023-06-21 2024-12-24 上海皓元医药股份有限公司 一种β-内酰胺酶抑制剂中间体及其制备方法
WO2025117677A1 (en) * 2023-11-29 2025-06-05 Actio Biosciences, Inc. Heterocyclic compounds useful as kcnt1 inhibitors
TW202608468A (zh) 2024-05-13 2026-03-01 美商基利科學股份有限公司 組合療法
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0086422A2 (en) * 1982-02-17 1983-08-24 GRUPPO LEPETIT S.p.A. Pharmacologically active pyrazolo(4,3-c)pyridines
WO2003035065A1 (en) * 2001-10-26 2003-05-01 Aventis Pharmaceuticals Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
WO2004013144A1 (en) * 2002-07-25 2004-02-12 Pharmacia Italia Spa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20060014756A1 (en) * 2001-10-26 2006-01-19 Aventis Pharmaceuticals Inc. Benzimidazoles
WO2010060854A1 (en) * 2008-11-25 2010-06-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
WO2011115804A1 (en) * 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2012036997A1 (en) * 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416527C (en) * 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7589202B2 (en) * 2000-08-14 2009-09-15 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
CN1642973A (zh) * 2000-09-06 2005-07-20 奥索-麦克尼尔药品公司 治疗变态反应的方法
CA2487679A1 (en) * 2002-05-30 2003-12-11 Vertex Pharmaceuticals Incorporated Inhibitors of jak and cdk2 protein kinases
CN1656079A (zh) * 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
US20060100233A1 (en) * 2002-07-25 2006-05-11 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2005030776A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
EP2303876B1 (en) * 2008-06-25 2014-03-19 Bristol-Myers Squibb Company Diketo azolopiperidines and azolopiperazines as anti-hiv agents
CN102282147B (zh) * 2009-01-28 2015-09-30 卡拉治疗学股份有限公司 二环吡唑并-杂环
AU2010282506A1 (en) * 2009-08-12 2012-03-08 Janssen Pharmaceutica Nv Process for the preparation of Cathepsin S inhibitors
WO2012087772A1 (en) * 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
KR101316101B1 (ko) * 2011-05-26 2013-10-11 연세대학교 산학협력단 Ｐｔｋ 6의 활성 억제용 조성물 및 이를 이용한 암 예방 및 치료용 조성물
CA2845473A1 (en) * 2011-09-12 2013-03-21 Sanofi Indanyl-substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
ES2559450T3 (es) 2011-09-16 2016-02-12 Sanofi 4,5,6,7-Tetrahidro-1H-pirazolo[4,3-c]piridinas sustituidas, su uso como medicamento, y preparaciones farmacéuticas que las comprenden
WO2013037914A1 (en) * 2011-09-16 2013-03-21 Sanofi Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
US10273243B2 (en) * 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
WO2016109689A2 (en) 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0086422A2 (en) * 1982-02-17 1983-08-24 GRUPPO LEPETIT S.p.A. Pharmacologically active pyrazolo(4,3-c)pyridines
WO2003035065A1 (en) * 2001-10-26 2003-05-01 Aventis Pharmaceuticals Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
US20060014756A1 (en) * 2001-10-26 2006-01-19 Aventis Pharmaceuticals Inc. Benzimidazoles
WO2004013144A1 (en) * 2002-07-25 2004-02-12 Pharmacia Italia Spa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2010060854A1 (en) * 2008-11-25 2010-06-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
WO2011115804A1 (en) * 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2012036997A1 (en) * 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters, 2013, Vol. 23 No. 4, pages 1070-1074 *
CAS Registry Number: 1028260-48-1; STN Entry Date: 15 June 2008 *
CAS Registry Number: 1087421-81-5; STN Entry Date: 21 December 2008 *
CAS Registry Number: 1087511-95-2; STN Entry Date: 21 December 2008 *
CAS Registry Number: 1332141-67-9; STN Entry Date: 14 September 2011 *
CAS Registry Number: 1332212-51-7; STN Entry Date: 14 September 2011 *
CAS Registry Number: 1351275-27-8; STN Entry Date: 19 December 2011 *
CAS Registry Number: 1574584-40-9; STN Entry Date: 27 March 2014 *
CAS Registry Number: 1574640-57-5; STN Entry Date: 27 March 2014 *
CAS Registry Number: 895835-76-4; STN Entry Date: 25 July 2006 *
CAS Registry Number: 903199-10-0; STN Entry Date: 22 August 2006 *
CAS Registry Number: 903853-89-4; STN Entry Date: 23 August 2006 *
CAS Registry Number: 906762-37-6; STN Entry Date: 15 September 2006 *
European Journal of Medicinal Chemistry, 2013, vol. 9, pages 356 - 364 *
Heterocycles, 1994, Vol. 37, No. 2, pages 967-978 *

Also Published As

Publication number Publication date
US10544141B2 (en) 2020-01-28
US10077264B2 (en) 2018-09-18
WO2016109689A3 (en) 2016-08-25
CN107531691A (zh) 2018-01-02
WO2016109684A2 (en) 2016-07-07
US9527845B2 (en) 2016-12-27
WO2016109689A2 (en) 2016-07-07
US9890161B2 (en) 2018-02-13
US20160185779A1 (en) 2016-06-30
WO2016109663A2 (en) 2016-07-07
US20180127415A1 (en) 2018-05-10
US9550779B2 (en) 2017-01-24
US10556904B2 (en) 2020-02-11
US20170121328A1 (en) 2017-05-04
CA2972434A1 (en) 2016-07-07
US20200181142A1 (en) 2020-06-11
US10538519B2 (en) 2020-01-21
US20160185778A1 (en) 2016-06-30
EP3240787A4 (en) 2018-06-20
US10093669B2 (en) 2018-10-09
KR20170118706A (ko) 2017-10-25
RU2017126995A3 (enExample) 2019-04-22
AU2020233640A1 (en) 2020-10-08
RU2742305C2 (ru) 2021-02-04
WO2016109663A3 (en) 2016-10-13
US20190194191A1 (en) 2019-06-27
US20170158691A1 (en) 2017-06-08
US20170121329A1 (en) 2017-05-04
AU2015373996A1 (en) 2017-07-13
RU2017126995A (ru) 2019-01-31
MX2017008720A (es) 2018-01-25
US20190031653A1 (en) 2019-01-31
JP2018500372A (ja) 2018-01-11
US9518057B2 (en) 2016-12-13
US20160185777A1 (en) 2016-06-30
JP6713465B2 (ja) 2020-06-24
MX383929B (es) 2025-03-14
US10189835B2 (en) 2019-01-29
US20190077800A1 (en) 2019-03-14
WO2016109684A3 (en) 2016-08-25
EP3240787A2 (en) 2017-11-08

Similar Documents

Publication Publication Date Title
AU2020233640A1 (en) Derivatives and methods of treating hepatitis B infections
AU2017286890B2 (en) Oxadiazepinone derivatives and their use in the treatment of hepatitis B infections
CA2928003A1 (en) Azepane derivatives and methods of treating hepatitis b infections
BRPI0918174A2 (pt) composto que apresenta atividade contra o vírus da hepatite c (hcv), sua composição e seu uso
US20220306647A1 (en) Novel indole-2-carboxamides active against the hepatitus b virus (hbv)
CA3097784A1 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
CA3147005A1 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
CA3138384A1 (en) Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
CA3136519A1 (en) Fused heterocycle derivatives as capsid assembly modulators
AU2020322598A1 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of HBV infection or of HBV-induced diseases
KR20220015421A (ko) Hbv 캡시드 조립 조절제로서의 아제핀

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired